ClinicalTrials.gg
CompletedNCT05989126Updated May 28, 2026Results posted

Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)

A Phase 3 interventional study of aflibercept 8 mg PFS in Diabetic Macular Edema (DME) and Neovascular Age-Related Macular Degeneration (nAMD), sponsored by Regeneron Pharmaceuticals. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-28.

Primary conditionMacular EdemaRegistry: Macular DegenerationReclassifiedWhy we changed it
Registry
Macular Degeneration — the first condition term the registry derived for this study.
ClinicalTrials.gg
Macular Edema
Why
  1. The study's listed conditions name Macular Edema, a narrower term within Macular Degeneration.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 53 studies testing aflibercept in Macular Edema — 1 open to participants now, 3 under way, 1 of them phase 3. aflibercept · Macular Edema.

Enrollment
36th of 53
35 · median 49
Started
2024
with 4 others
Phase 3
11 of 53
none open now
Registered
48th of 53
by date
Lead sponsor
6 of 53
Regeneron Pharmaceuticals

Among the 53 studies testing aflibercept in Macular Edema, this one is the 36th largest by enrollment, is one of 5 that started in 2024, is one of 11 in phase 3, and was the 48th registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

Browse Macular Edema studies →

Open to participants now

1 of the 53 studies testing aflibercept in Macular Edema is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About aflibercept

aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies testing aflibercept in Macular Edema, or all of them as a file.
02

Study summary

Regeneron Pharmaceuticals developed a single-dose pre-filled syringe (PFS) to deliver 8 mg aflibercept. The PFS is a convenient device that contains the study medication that will be injected in your study eye. A PFS offers a sterile, single dose of study drug within the syringe; this eliminates the need for the retina specialist to prepare the injection syringe from a separate vial.

This Phase IIIb study is focused on patients with diabetic macular edema (DME) and neovascular (wet) age-related macular degeneration (nAMD).

The main aim of the study is to evaluate if the 8 mg aflibercept PFS allows for successful preparation and administration of 8 mg aflibercept by retina specialists. The study will also assess the safety of 8 mg aflibercept PFS use. Regeneron will use the information from the study to better understand if the PFS can be used safely and effectively by retina specialists to administer 8 mg aflibercept.

03

Conditions studied

  • Diabetic Macular Edema (DME)
  • Neovascular Age-Related Macular Degeneration (nAMD)

Browse trials for

Keywords

  • Neovascular "wet" age-related macular degeneration
04

In context

Macular Edema Reclassified

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

This study's enrollment of 35 is below the median of 56 across 586 interventional studies indexed under Macular Edema.

Browse Macular Edema studies →

Lead sponsor

Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.

Compared within Macular Edema, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Macular Degeneration. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Patient must have diabetic macular edema (DME) or neovascular "wet" age-related macular degeneration (nAMD) in the study eye
  2. Study eye considered by the retina specialist to be eligible for treatment with 8 mg aflibercept

Key Exclusion Criteria:

  1. Any active intraocular inflammation or infection in either eye or history of intraocular inflammation or infection after past IVT injections with any agent in either eye
  2. Treatment with any IVT injection in the study eye within the 25 days prior to day 1
  3. Intraocular pressure (IOP) >25 mm Hg in the study eye at screening
  4. Any intraocular surgery in the study eye at any time during the past 3 months
  5. Any prior extended-release therapeutic agent, or ocular drug-release device implantation (approved or , including ) in the study eye

NOTE: Other protocol Defined Inclusion/Exclusion Criteria Apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    8 mg Dose

    Only 1 eye will be selected as the study eye by the investigator. Patients will receive a single dose utilizing the PFS.

    Drug: aflibercept 8 mg PFS

Interventions

  • Sterile aqueous solution in a single-dose PFS administered by intravitreal (IVT) injection

    Also known as: EYLEA ® HD, BAY86-5321

07

What researchers measure

Primary outcomes

  1. Number of 8 mg Aflibercept Injections Successfully Administered Utilizing the PFS

    Participants received a single dose of study drug, administered in the selected study eye with the PFS by a retina specialist. Physician assessed successful aflibercept preparation and administration with the PFS.

    Time frame: At Day 1

Secondary outcomes

  1. Number of Participants With at Least One Ocular Treatment-emergent Adverse Event (TEAE) in the Study Eye

    Time frame: Through Day 29

  2. Number of Participants With at Least One Ocular Serious TEAE in the Study Eye

    Time frame: Through Day 29

08

Results

Posted May 28, 2026

Participant flow

Participant flow — Overall Study
MilestoneAflibercept 8 mg PFS
Started35
Completed35
Not completed0

Outcome measures

PrimaryNumber of 8 mg Aflibercept Injections Successfully Administered Utilizing the PFS

Participants received a single dose of study drug, administered in the selected study eye with the PFS by a retina specialist. Physician assessed successful aflibercept preparation and administration with the PFS.

Time frame:
At Day 1
Reported as:
Number · injections
Number of 8 mg Aflibercept Injections Successfully Administered Utilizing the PFS
injectionsAflibercept 8 mg PFS
Number of 8 mg Aflibercept Injections Successfully Administered Utilizing the PFS35
SecondaryNumber of Participants With at Least One Ocular Treatment-emergent Adverse Event (TEAE) in the Study Eye
Time frame:
Through Day 29
Reported as:
Count of participants · Participants
Number of Participants With at Least One Ocular Treatment-emergent Adverse Event (TEAE) in the Study Eye
ParticipantsAflibercept 8 mg PFS
Number of Participants With at Least One Ocular Treatment-emergent Adverse Event (TEAE) in the Study Eye2
SecondaryNumber of Participants With at Least One Ocular Serious TEAE in the Study Eye
Time frame:
Through Day 29
Reported as:
Count of participants · Participants
Number of Participants With at Least One Ocular Serious TEAE in the Study Eye
ParticipantsAflibercept 8 mg PFS
Number of Participants With at Least One Ocular Serious TEAE in the Study Eye0

Adverse events

Collected over From date of informed consent to end of study (up to approximately 43 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aflibercept 8 mg PFS0/35 (0%)2/35 (5.7%)2/35 (5.7%)
Most frequent serious events
Most frequent serious events
EventAflibercept 8 mg PFS
Intestinal obstructionGastrointestinal disorders1/35
CholelithiasisHepatobiliary disorders1/35
Most frequent other events
Most frequent other events
EventAflibercept 8 mg PFS
HypertensionVascular disorders2/35

Baseline characteristics

Safety analysis set (SAF): All enrolled participants who received any study drug. Only one study eye per participant was analyzed within the study.

Age, Continuous
Age, Continuous(years)Aflibercept 8 mg PFS
Mean70.4 ± 14.27
Sex: Female, Male
Sex: Female, Male(Participants)Aflibercept 8 mg PFS
Female25
Male10
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Aflibercept 8 mg PFS
Hispanic or Latino4
Not Hispanic or Latino31
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Aflibercept 8 mg PFS
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American6
White28
More than one race0
Unknown or Not Reported0
09

Study locations

2 sites
  • Retina Consultants of Texas
    Bellaire, Texas 77401, United States
  • Retina Consultants of Texas
    The Woodlands, Texas 77385, United States
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in May 2024, 1 month.

Results were first posted in May 2026, 1 year 11 months after primary completion. A results delay was requested in May 2025.

Of 52 industry-sponsored phase 3 interventional studies under Macular Edema, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 33. This study's 1 month is below that.

Counting every sponsor, half of 65 studies reached it within 25 months; a quarter within 18 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2023
First posted
Aug 14, 2023
StartActual
Apr 15, 2024
Primary completionActual
May 31, 2024
CompletionActual
May 31, 2024
Results delay requested
May 29, 2025
Results first posted
May 28, 2026
Last update
May 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT05989126
Responsible party
Sponsor
First posted
Aug 14, 2023
Start date
Apr 15, 2024
Primary completion
May 31, 2024
Completion
May 31, 2024
Results posted
May 28, 2026
Last update
May 28, 2026

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion